MEIP - MEI Pharma Inc Stock Price, Fair Value and News

3.16USD+0.03 (+0.96%)Market Closed

Market Summary

USD3.16+0.03

Market Closed

0.96%

MEIP Stock Price

View Fullscreen

MEIP RSI Chart

MEIP Valuation

Market Cap

20.9M

Price/Earnings (Trailing)

1.05

Price/Sales (Trailing)

0.29

Price/Free Cashflow

-0.39

MEIP Price/Sales (Trailing)

MEIP Profitability

Return on Equity

33.36%

Return on Assets

25.27%

Free Cashflow Yield

-256.29%

MEIP Fundamentals

MEIP Revenue

Revenue (TTM)

72.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

MEIP Earnings

Earnings (TTM)

19.8M

Earnings Growth (Yr)

-207.9%

Earnings Growth (Qtr)

-119.62%

Breaking Down MEIP Revenue

52 Week Range

3.067.97

(Low)(High)

Last 7 days

2.9%

Last 30 days

-16.3%

Last 90 days

-30.4%

Trailing 12 Months

-55.1%

How does MEIP drawdown profile look like?

MEIP Financial Health

Current Ratio

8.23

MEIP Investor Care

Buy Backs (1Y)

0.00%

Diluted EPS (TTM)

2.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	58.8M	48.8M	105.4M	72.6M
2022	36.7M	40.7M	41.7M	62.6M
2021	52.8M	34.8M	35.9M	35.2M
2020	4.5M	28.9M	34.4M	46.0M
2019	4.3M	4.9M	5.6M	4.5M
2018	7.0M	1.6M	1.8M	3.5M
2017	18.6M	23.2M	17.8M	12.4M
2016	118.0K	4.7M	9.4M	14.0M
2015	71.0K	78.0K	93.0K	109.0K
2014	79.0K	81.0K	75.0K	60.0K
2013	22.0K	37.0K	52.0K	75.0K
2012	61.8K	39.0K	39.0K	39.0K
2011	0	130.0K	107.3K	84.5K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MEI Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 20, 2023	funicular funds, lp	acquired	844,200	7.00	120,600	-
Oct 20, 2023	anson funds management lp	acquired	1,253,000	7.00	179,000	-
Oct 11, 2023	funicular funds, lp	acquired	210,000	7.00	30,000	-
Oct 11, 2023	anson funds management lp	acquired	350,000	7.00	50,000	-
Sep 22, 2023	funicular funds, lp	bought	219,554	6.8525	32,040	-
Sep 22, 2023	anson funds management lp	bought	329,331	6.8525	48,060	-
Sep 21, 2023	funicular funds, lp	bought	144,740	6.4616	22,400	-
Sep 21, 2023	anson funds management lp	bought	217,110	6.4616	33,600	-
Sep 20, 2023	funicular funds, lp	bought	480,744	6.0093	80,000	-
Sep 20, 2023	anson funds management lp	bought	721,116	6.0093	120,000	-

Which funds bought or sold MEIP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	HighMark Wealth Management LLC	unchanged	-	-525	1,167	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	11,000	11,000	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-3,598	7,996	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.63	-427,783	2,260,880	-%
Feb 20, 2024	Cable Car Capital LLC	new	-	3,546,350	3,546,350	3.68%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	46.27	27,073	155,840	-%
Feb 14, 2024	LAZARD ASSET MANAGEMENT LLC	new	-	2,000	2,000	-%

Are Funds Buying or Selling MEIP?

Are funds buying MEIP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MEIP

No. of Funds

Unveiling MEI Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	4.9%	326,084	SC 13G/A
Feb 13, 2024	vanguard group inc	5.85%	389,807	SC 13G/A
Nov 01, 2023	anson funds management lp	9.2%	611,440	SC 13D/A
Oct 24, 2023	anson funds management lp	9.2%	611,440	SC 13D/A
Oct 13, 2023	anson funds management lp	7.4%	490,840	SC 13D/A
Sep 26, 2023	anson funds management lp	6.9%	460,840	SC 13D/A
Sep 22, 2023	anson funds management lp	6.4%	428,800	SC 13D/A
Sep 15, 2023	anson funds management lp	4.9%	326,400	SC 13D/A
Aug 08, 2023	anson funds management lp	4.9%	326,400	SC 13D/A
Jul 17, 2023	anson funds management lp	4.9%	326,400	SC 13D/A

Recent SEC filings of MEI Pharma Inc

View All Filings

Date Filed	Form Type	Document
Feb 28, 2024	424B5	Prospectus Filed
Feb 28, 2024	EFFECT	EFFECT
Feb 26, 2024	CORRESP	CORRESP
Feb 23, 2024	UPLOAD	UPLOAD
Feb 21, 2024	8-K	Current Report
Feb 20, 2024	S-3	S-3
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	8-K	Current Report
Feb 13, 2024	10-Q	Quarterly Report

Peers (Alternatives to MEI Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

MEI Pharma Inc News

Latest updates

MEI Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	65,297,000	1,457,000	5,894,000	32,735,000	8,730,000	11,414,000	9,694,000	11,832,000	7,757,000	7,454,000	8,109,000	12,595,000	6,638,000	25,504,000	1,244,000	1,008,000	1,157,000	1,129,000	1,249,000	2,049,000
Costs and Expenses	19.1%	11,930,000	10,016,000	12,537,000	22,285,000	23,809,000	26,949,000	27,610,000	31,252,000	29,457,000	27,862,000	22,928,000	24,504,000	28,368,000	19,420,000	12,869,000	13,687,000	13,117,000	13,780,000	12,878,000	13,865,000	13,896,000
Operating Expenses	-	-	-	-	12,238,000	-	-	-	13,059,000	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	22.8%	8,018,000	6,531,000	9,967,000	7,181,000	8,496,000	7,486,000	5,771,000	8,934,000	7,926,000	7,909,000	6,634,000	6,215,000	5,650,000	5,915,000	4,528,000	3,864,000	4,195,000	4,130,000	3,744,000	3,631,000	3,821,000
R&D Expenses	12.3%	3,912,000	3,485,000	2,570,000	15,104,000	15,313,000	19,463,000	21,839,000	22,318,000	21,531,000	19,953,000	16,294,000	17,884,000	22,224,000	12,996,000	7,859,000	8,963,000	8,281,000	8,962,000	8,032,000	9,071,000	9,066,000
EBITDA Margin	-	-	-	-	-	-0.86	-1.30	-1.33	-1.37	-1.43	-1.40	-1.45	-0.87	-1.00	-1.33	-1.59	-3.68	-3.68	-2.99	-3.41	-9.23	-11.37
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	16,000	-	-	-8,000	2,000	-	-	-1,000	2,000	-	-
EBT Margin	-	-	-	-	-	-0.87	-1.31	-1.34	-1.38	-1.44	-1.41	-1.45	-0.87	-1.00	-1.34	-1.59	-3.71	-3.70	-3.01	-3.42	-9.25	-11.39
Net Income	-119.6%	-11,063,000	56,374,000	-10,029,000	-15,438,000	10,253,000	-16,624,000	-16,063,000	-8,725,000	-12,156,000	-17,510,000	-8,378,000	-25,622,000	-8,026,000	712,000	-18,476,000	-4,329,000	-20,217,000	-2,994,000	3,052,000	-17,354,000	12,025,000
Net Income Margin	-30.1%	0.27	0.39	-0.65	-0.64	-0.50	-1.29	-1.34	-1.27	-1.81	-1.70	-1.19	-1.48	-	-	-	-	-	-	-	-	-
Free Cashflow	40.2%	-11,055,000	-18,491,000	-11,302,000	-12,600,000	-14,333,000	-14,845,000	-15,810,000	-13,552,000	-8,617,000	-7,729,000	-11,265,000	-15,646,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-22.4%	79.00	101	121	134	42.00	164	178	194	85.00	176	174	186	204	214	210	97.00	107	69.00	83.00	86.00	96.00
Current Assets	-25.2%	66.00	88.00	108	120	40.00	149	167	183	82.00	167	165	177	194	204	209	95.00	106	68.00	82.00	85.00	96.00
Cash Equivalents	53.4%	5.00	3.00	17.00	9.00	38.00	15.00	16.00	53.00	81.00	16.00	9.00	10.00	10.00	11.00	12.00	7.00	9.00	6.00	10.00	7.00	9.00
Net PPE	-6.9%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
Liabilities	-4.2%	19.00	20.00	96.00	100	61.00	126	125	127	63.00	142	125	141	125	130	133	22.00	30.00	22.00	35.00	48.00	43.00
Current Liabilities	-6.1%	8.00	9.00	20.00	24.00	14.00	23.00	24.00	24.00	13.00	21.00	20.00	33.00	22.00	18.00	14.00	10.00	10.00	10.00	14.00	12.00	11.00
Shareholder's Equity	-26.9%	59.00	81.00	25.00	34.00	48.00	37.00	52.00	68.00	73.00	34.00	49.00	56.00	79.00	84.00	77.00	74.00	77.00	47.00	48.00	38.00	53.00
Retained Earnings	-3.2%	-360	-349	-406	-395	-396	-390	-374	-358	-811	-337	-319	-322	-285	-277	-278	-258	-254	-234	-231	-234	-216
Additional Paid-In Capital	-2.5%	420	431	431	430	837	428	427	426	833	372	369	367	364	362	355	333	332	281	279	272	270
Shares Outstanding	0%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	32.00	-	-	-	353	-	-	-	301	-	-	-	262	-	-	-	187

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	40.2%	-11,055	-18,491	-11,302	-12,600	-14,270	-14,782	-15,504	-13,535	-8,566	-7,721	-11,257	-15,646	4,050	-9,111	69,112	-10,295	-10,481	-14,078	-8,064	-11,342	2,799
Share Based Compensation	134.2%	850	363	299	918	813	1,559	650	2,837	2,324	2,539	2,049	2,645	2,609	2,942	1,367	1,550	1,771	2,113	1,448	1,514	1,663
Cashflow From Investing	394.6%	24,517	4,957	19,396	-	10,534	13,735	20,112	-14,066	-43,369	14,993	9,988	15,388	-5,144	4,476	-85,048	9,103	-35,316	4,967	9,955	9,768	-193
Cashflow From Financing	-Infinity%	-11,660	-	-	-	-	-40.00	20.00	360	48,865	-194	67.00	126	15.00	3,260	20,829	-8.00	48,451	5,505	273	252	24.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MEIP Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 0	$ 32,735	$ 65,297	$ 41,465
Operating expenses:
Research and development	3,912	15,313	7,397	34,776
General and administrative	8,018	8,496	14,549	15,982
Total operating expenses	11,930	23,809	21,946	50,758
(Loss) income from operations	(11,930)	8,926	43,351	(9,293)
Other income (expense):
Change in fair value of warrant liability	0	486	0	1,603
Interest and dividend income	869	845	1,963	1,325
Other expense, net	(2)	(4)	(3)	(6)
Total other income, net	867	1,327	1,960	2,922
Net (loss) income	$ (11,063)	$ 10,253	$ 45,311	$ (6,371)
Net (loss) income per share - basic and diluted:
Basic	$ (1.66)	$ 1.54	$ 6.8	$ (0.96)
Diluted	$ (1.66)	$ 1.54	$ 6.8	$ (0.96)
Weighted-average shares used in computing net (loss) income per share - basic and diluted:
Basic	6,663	6,663	6,663	6,663
Diluted	6,663	6,663	6,663	6,663
Revenue from customers
Revenues	$ 0	$ 32,735	$ 752	$ 41,465
Revenue from collaboration agreements
Revenues	$ 0	$ 0	$ 64,545	$ 0

MEIP Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 5,174	$ 16,906
Short-term investments	54,306	83,787
Unbilled receivables	0	85
Prepaid expenses and other current assets	6,692	6,750
Total current assets	66,172	107,528
Operating lease right-of-use asset	11,222	11,972
Property and equipment, net	1,144	1,309
Total assets	78,538	120,809
Current liabilities:
Accounts payable	1,378	6,134
Accrued liabilities	5,645	12,461
Deferred revenue	0	317
Operating lease liability	1,015	1,428
Total current liabilities	8,038	20,340
Deferred revenue, long-term	0	64,545
Operating lease liability, long-term	11,012	11,300
Total liabilities	19,050	96,185
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding	0	0
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at December 31, 2023 and June 30, 2023.	0	0
Additional paid-in capital	420,174	430,621
Accumulated deficit	(360,686)	(405,997)
Total stockholders' equity	59,488	24,624
Total liabilities and stockholders' equity	$ 78,538	$ 120,809

About MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

CEO	Mr. David M. Urso B.A., Esq., J.D.
WEBSITE	meipharma.com
INDUSTRY	Biotechnology
EMPLOYEES	102

MEI Pharma Inc Frequently Asked Questions

What is the ticker symbol for MEI Pharma Inc? What does MEIP stand for in stocks?

MEIP is the stock ticker symbol of MEI Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MEI Pharma Inc (MEIP)?

As of Tue May 07 2024, market cap of MEI Pharma Inc is 20.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEIP stock?

You can check MEIP's fair value in chart for subscribers.

What is the fair value of MEIP stock?

You can check MEIP's fair value in chart for subscribers. The fair value of MEI Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MEI Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEIP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MEI Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether MEIP is over valued or under valued. Whether MEI Pharma Inc is cheap or expensive depends on the assumptions which impact MEI Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEIP.

What is MEI Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, MEIP's PE ratio (Price to Earnings) is 1.05 and Price to Sales (PS) ratio is 0.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MEI Pharma Inc's stock?

In the past 10 years, MEI Pharma Inc has provided -0.076 (multiply by 100 for percentage) rate of return.